Skip to main content

Day: November 4, 2024

Statkraft AS: Release of third quarter results 2024

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Statkraft discloses third quarter results for 2024 on Thursday 7 November 2024 at 08:00 a.m. CET. Documents will be available on Statkraft’s website www.statkraft.com and Oslo Stock Exchange’s news service www.newsweb.no. Webcast09:30 a.m. CET: Statkraft presents the results in a webcast at www.statkraft.com. The presentation will be held in English. Contact:Arild Ratikainen, Investor Contact, tlf.: +47 971 74 132, e-mail: arild.ratikainen@statkraft.com

Continue reading

Danske Bank share buy-back programme: Transactions in week 44

Written by Customer Service on . Posted in Public Companies.

Company announcement no. 49 2024  Group CommunicationsBernstorffsgade 40DK-1577 København VTel. +45 45 14 00 00 4 November 2024Danske Bank share buy-back programme: Transactions in week 44 On 2 February 2024, Danske Bank A/S announced a share buy-back programme for a total of DKK 5.5 billion, with a maximum of 70 million shares, in the period from 5 February 2024 to 31 January 2025, at the latest, as described in company announcement no. 2 2024. The programme is being carried out under Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016, also referred to as the Safe Harbour Rules. The following transactions were made under the share buy-back programme in week 44:  Number of shares VWAP DKK Gross valueDKKAccumulated,...

Continue reading

Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3 Through October more than 2,200 unique prescribers and more than 5,000 prescriptions filled across a broad COPD population Pipeline expansion continues: Phase 2 programs enrolling Conference call today at 9:00 a.m. ET / 2:00 p.m. GMT LONDON and RALEIGH, N.C., Nov. 04, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the third quarter ended September 30, 2024, and provides a corporate update. “We are pleased to report an exceptionally strong start to the US launch of Ohtuvayre (ensifentrine) with healthcare professionals (HCPs) prescribing treatment across a broad range of chronic...

Continue reading

Bureau Veritas strengthens its Buildings & Infrastructure leadership position in Asia-Pacific with an agreement to acquire The APP Group

Written by Customer Service on . Posted in Mergers And Acquisitions.

PRESS RELEASE Paris – November 4, 2024 Bureau Veritas strengthens its Buildings & Infrastructure leadership position in Asia-Pacific with an agreement to acquire The APP Group Bureau Veritas, a global leader in Testing, Inspection, and Certification services, announced today that it has signed an agreement to acquire The APP Group, a leading provider of Assurance, Compliance, Independent Verification and Certification (IV/IC), Construction Supervision, Project Management, Strategic Advisory and Asset Management and Optimization Services across the full asset investment lifecycle in the Buildings and Infrastructure sectors in Australia. This strategic move will significantly enhance Bureau Veritas’ presence in the Asia-Pacific region and develop its capabilities to support infrastructure projects. This acquisition is aligned...

Continue reading

Investor Day 2024: Clariant well positioned for further growth and profitability improvement

Written by Customer Service on . Posted in Public Companies.

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR  Clariant committed to creating shareholder value as a top quartile specialty chemical company Differentiated segment steering and adoption of strategic mandates to drive above-market growth Innovation arenas to deliver ~ 70 % of profitable growth and innovation rate expected to reach ~ 20 % by 2027 Reinforced medium-term financial targets, by 2027 at the latest: compound annual sales growth of 4 – 6 % in local currency, EBITDA margin of 19 – 21 %, and free cash flow conversion of around 40 % Margin improvement reinforced by new self-help actions totaling ~ CHF 80 million run-rate savings in full by latest 2027 Upgraded 2030 non-financial targets, including increased GHG emission reduction targets in line with SBTi 1.5°C scenario “At Clariant, we have built...

Continue reading

Talen Energy Statement on FERC Order Rejecting Susquehanna ISA

Written by Customer Service on . Posted in Public Companies.

HOUSTON, Nov. 03, 2024 (GLOBE NEWSWIRE) — Talen Energy Corporation (“Talen”) (NASDAQ: TLN) released the following statement in response to Friday’s Federal Energy Regulatory Commission (the “FERC”) order rejecting the amended Susquehanna Interconnection Service Agreement (“ISA”) between PJM Interconnection (“PJM”), PPL Electric Utilities (“PPL”), and Talen which would increase co-located load capacity at Talen’s Susquehanna nuclear power generation facility from 300 megawatts to 480 megawatts: On Friday, FERC issued an order denying PJM, PPL, and Talen’s Susquehanna ISA. Talen believes FERC erred and we are evaluating our options, with a focus on commercial solutions. We believe this ISA amendment is just and reasonable and in the best interest of consumers. FERC’s decision will have a chilling effect on economic development...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.